Filing Details

Accession Number:
0001209191-18-056084
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-10-24 17:21:02
Reporting Period:
2018-10-23
Accepted Time:
2018-10-24 17:21:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
820081 Cambrex Corp CBM Pharmaceutical Preparations (2834) 222476135
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1192621 M Steven Klosk One Meadowlands Plaza
East Rutherford NJ 07073
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-10-23 20,000 $17.81 103,328 No 4 M Direct
Common Stock Disposition 2018-10-23 16,805 $54.67 86,523 No 4 S Direct
Common Stock Disposition 2018-10-23 3,195 $55.27 83,328 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2018-10-23 20,000 $0.00 20,000 $17.81
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2021-10-22 No 4 M Direct
Footnotes
  1. The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.16 to $55.10 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 2 to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.18 to $55.38 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4.
  4. The option representing a right to purchase 80,000 shares became exercisable in four equal installments beginning October 22, 2015, which was the first anniversary of the date on which the option was granted.